1
|
Kraft M, Wiedmann F, Foerster KI, Sauter M, Paasche A, Blochberger PL, Yesilgoez B, L'hoste Y, Arif R, Warnecke G, Karck M, Frey N, Burhenne J, Haefeli WE, Schmidt C. Comparison of the antiarrhythmic potential of doxapram and its metabolite ketodoxaparam. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
A few years ago, the TASK-1 channel has been established as a potential new target for the therapy of atrial fibrillation (AF). In the heart, TASK-1 is almost exclusively expressed in the atria and is significantly upregulated in AF patients. Therefore, it plays an important role in the shortening of the atrial action potential observed during AF, making TASK-1 a promising target for AF therapy. This could be proven in a porcine model of persistent AF in which an intravenous application of the TASK-1 inhibitor doxapram led to a termination of AF and the restoration of sinus rhythm (SR). Doxapram's metabolite ketodoxapam is described in the literature as being active with limited data available on its usage. Therefore, the effect of ketodoxapram on TASK-1 and its possible use in AF therapy still needs to be investigated.
Purpose
The purpose of the present study was to assess the potential of ketodoxapram in the termination of AF. Furthermore, a comparison between doxapram and ketodoxapram was performed based on electrophysiological and pharmacological data.
Methods
UPLC-MS/MS assays were developed and validated for the measurement of doxapram and ketodoxapram in porcine plasma and brain tissue. Using these assays, the pharmacokinetics of both substances, after intravenous injections of 1 mg/kg, were determined in pigs. Furthermore, brain and plasma concentrations were measured to assess brain-to-plasma ratios. A porcine AF model was used to estimate the antiarrhythmic potential. Electrophysiological properties were evaluated, using two-electrode voltage clamp experiment on Xenopus laevis oocytes which heterologously expressed atrial potassium channels, to calculate the effect of doxapram and ketodoxapram on channel function. Furthermore, whole-cell patch clamp measurements were performed on isolated human cardiomyocytes.
Results
Doxapram and ketodoxapram showed strong inhibitory effects on TASK-1 (IC50 1.0 μM and 0.8 μM) and TASK-3 (5.9 μM and 1.5 μM), but no significant effect on the other measured ion channels. The maximal inhibition on TASK-1 was 96%. The brain-to-plasma ratio for doxapram (0.58) was almost ten-fold higher than for ketodoxapram (0.065), hinting at a reduced crossing of the blood-brain barrier (BBB) for ketodoxapram. The terminal half-life (t1/2) of ketodoxapram (1.71 h) was longer and the maximal concentration (Cmax; 4,604 ng/ml) was higher than for doxapram (1.38 h; 1,780 ng/ml). In a porcine model of AF, ketodoxapram led to a significantly reduced AF burdens comparable to doxapram.
Conclusions
Doxapram and ketodoxapram both show strong inhibitory effects on TASK-1, making them good candidates for a TASK-1 based AF therapy. Ketodoxapram with its longer t1/2, reduced crossing of the BBB and higher Cmax points towards a possible superiority in the treatment of AF compared to doxapram. Studies in a porcine AF model showed promising results for the use of doxapram and ketodoxapram in AF therapy.
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): German Research Foundation
Collapse
Affiliation(s)
- M Kraft
- University Hospital of Heidelberg , Heidelberg , Germany
| | - F Wiedmann
- University Hospital of Heidelberg , Heidelberg , Germany
| | - K I Foerster
- University Hospital of Heidelberg , Heidelberg , Germany
| | - M Sauter
- University Hospital of Heidelberg , Heidelberg , Germany
| | - A Paasche
- University Hospital of Heidelberg , Heidelberg , Germany
| | | | - B Yesilgoez
- University Hospital of Heidelberg , Heidelberg , Germany
| | - Y L'hoste
- University Hospital of Heidelberg , Heidelberg , Germany
| | - R Arif
- University Hospital of Heidelberg , Heidelberg , Germany
| | - G Warnecke
- University Hospital of Heidelberg , Heidelberg , Germany
| | - M Karck
- University Hospital of Heidelberg , Heidelberg , Germany
| | - N Frey
- University Hospital of Heidelberg , Heidelberg , Germany
| | - J Burhenne
- University Hospital of Heidelberg , Heidelberg , Germany
| | - W E Haefeli
- University Hospital of Heidelberg , Heidelberg , Germany
| | - C Schmidt
- University Hospital of Heidelberg , Heidelberg , Germany
| |
Collapse
|
2
|
Wittmann F, Czock D, Frese T, Gensichen J, Haefeli W, Hoffmann W, Kaduszkiewicz H, König HH, Thyrian JR, Wiese B, Luppa M, Riedel-Heller SG. COVID-19 measures and their impact on mental health of older people
and the effect of perceived stress and resilience. Das Gesundheitswesen 2022. [DOI: 10.1055/s-0042-1753739] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- F Wittmann
- Universität Leipzig, Institut für Sozialmedizin,
Arbeitsmedizin und Public Health (ISAP), Leipzig, Deutschland
| | - D Czock
- Universitätsklinikum Heidelberg, Department of Clinical
Pharmacology and Pharmacoepidemiology, Heidelberg, Deutschland
| | - T Frese
- Martin-Luther Universität Halle-Wittenberg, Institute of
General Practice and Family Medicine, Halle, Deutschland
| | - J Gensichen
- Universität München, Institute of General Practice and
Family Medicine, München, Deutschland
| | - W Haefeli
- Martin-Luther Universität Halle-Wittenberg, Institute of
General Practice and Family Medicine, Halle, Deutschland
| | - W Hoffmann
- Universität Rostock, Deutsches Zentrum für
Neurodegenerative Erkrankungen, Greifswald, Deutschland
- Universität Greifswald, Institute for Community Medicine,
Greifswald, Deutschland
| | - H Kaduszkiewicz
- Universität Kiel, Institute of General Practice, Kiel,
Deutschland
| | - H-H König
- Universität Hamburg, Department of Health Economics and Health
Service Research, Hamburg, Deutschland
| | - JR Thyrian
- Universität Rostock, Deutsches Zentrum für
Neurodegenerative Erkrankungen, Greifswald, Deutschland
| | - B Wiese
- Medizinische Hochschule Hannover, Institute for General Practice,
Hannover, Deutschland
| | - M Luppa
- Universität Leipzig, Institut für Sozialmedizin,
Arbeitsmedizin und Public Health (ISAP), Leipzig, Deutschland
| | - SG Riedel-Heller
- Universität Leipzig, Institut für Sozialmedizin,
Arbeitsmedizin und Public Health (ISAP), Leipzig, Deutschland
| |
Collapse
|
3
|
Claus M, Luppa M, Czock D, Frese T, Gensichen J, Haefeli W, Hoffmann W, Kaduszkiewicz H, König HH, Wiese B, Thyrian JR, Riedel-Heller SG. Association of modifiable lifestyle factors with cognitive function
in the AgeWell.de-trial. Das Gesundheitswesen 2022. [DOI: 10.1055/s-0042-1753678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- M Claus
- Medical Faculty, University of Leipzig, Institute of Social Medicine,
Occupational Health and Public Health (ISAP), Leipzig, Deutschland
| | - M Luppa
- Medical Faculty, University of Leipzig, Institute of Social Medicine,
Occupational Health and Public Health (ISAP), Leipzig, Deutschland
| | - D Czock
- University Hospital Heidelberg, Department of Clinical Pharmacology and
Pharmacoepidemiology, Heidelberg, Deutschland
| | - T Frese
- Martin-Luther-University Halle-Wittenberg, Institute of General
Practice and Family Medicine, Halle (Saale), Deutschland
| | - J Gensichen
- University of LMU Munich, Institute of General Practice and Family
Medicine, Munich, Deutschland
| | - W Haefeli
- University Hospital Heidelberg, Department of Clinical Pharmacology and
Pharmacoepidemiology, Heidelberg, Deutschland
| | - W Hoffmann
- University Medicine Greifswald, Institute for Community Medicine,
Greifswald, Deutschland
- German Center for Neurodegenerative Diseases (DZNE), Site
Rostock/Greifswald, Greifswald, Deutschland
| | - H Kaduszkiewicz
- University of Kiel, Institute of General Practice, Kiel,
Deutschland
| | - H-H König
- University Medical Center Hamburg-Eppendorf, Department of Health
Economics and Health Services Research, Hamburg, Deutschland
| | - B Wiese
- Hannover Medical School, Institute for General Practice, Work Group
Medical Statistics and IT-Infrastructure, Hannover, Deutschland
| | - JR Thyrian
- University Medicine Greifswald, Institute for Community Medicine,
Greifswald, Deutschland
- German Center for Neurodegenerative Diseases (DZNE), Site
Rostock/Greifswald, Greifswald, Deutschland
| | - SG Riedel-Heller
- Medical Faculty, University of Leipzig, Institute of Social Medicine,
Occupational Health and Public Health (ISAP), Leipzig, Deutschland
| |
Collapse
|
4
|
Wild B, Wurmbach VS, Böhlen F, Kusch MKP, Seidling HM, Reich P, Hartmann M, Haefeli WE, Friederich HC, Slaets J. Assessing the perspective of well-being of older patients with multiple morbidities by using the LAVA tool - a person-centered approach. BMC Geriatr 2021; 21:427. [PMID: 34271859 PMCID: PMC8285789 DOI: 10.1186/s12877-021-02342-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2021] [Accepted: 06/13/2021] [Indexed: 12/30/2022] Open
Abstract
Background Older patients with multiple morbidities are a particularly vulnerable population that is likely to face complex medical decisions at some time in their lives. A patient-centered medical care fosters the inclusion of the patients’ perspectives, priorities, and complaints into clinical decision making. Methods This article presents a short and non-normative assessment tool to capture the priorities and problems of older patients. The so-called LAVA (“Life and Vitality Assessment”) tool was developed for practical use in seniors in the general population and for residents in nursing homes in order to gain more knowledge about the patients themselves as well as to facilitate access to the patients. The LAVA tool conceptualizes well-being from the perspectives of older individuals themselves rather than from the perspectives of outside individuals. Results The LAVA tool is graphically presented and the assessment is explained in detail. Exemplarily, the outcomes of the assessments with the LAVA of three multimorbid older patients are presented and discussed. In each case, the assessment pointed out resources as well as at least one problem area, rated as very important by the patients themselves. Conclusions The LAVA tool is a short, non-normative, and useful approach that encapsulates the perspectives of well-being of multimorbid patients and gives insights into their resources and problem areas. Supplementary Information The online version contains supplementary material available at 10.1186/s12877-021-02342-3.
Collapse
Affiliation(s)
- B Wild
- Department of General Internal Medicine and Psychosomatics, Heidelberg University Hospital, 69120, Heidelberg, Germany.
| | - V S Wurmbach
- Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, 69120, Heidelberg, Germany.,Cooperation Unit Clinical Pharmacy, Heidelberg University Hospital, 69120, Heidelberg, Germany
| | - F Böhlen
- Department of General Internal Medicine and Psychosomatics, Heidelberg University Hospital, 69120, Heidelberg, Germany
| | - M K-P Kusch
- Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, 69120, Heidelberg, Germany.,Cooperation Unit Clinical Pharmacy, Heidelberg University Hospital, 69120, Heidelberg, Germany
| | - H M Seidling
- Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, 69120, Heidelberg, Germany.,Cooperation Unit Clinical Pharmacy, Heidelberg University Hospital, 69120, Heidelberg, Germany
| | - P Reich
- Department of General Internal Medicine and Psychosomatics, Heidelberg University Hospital, 69120, Heidelberg, Germany
| | - M Hartmann
- Department of General Internal Medicine and Psychosomatics, Heidelberg University Hospital, 69120, Heidelberg, Germany
| | - W E Haefeli
- Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, 69120, Heidelberg, Germany.,Cooperation Unit Clinical Pharmacy, Heidelberg University Hospital, 69120, Heidelberg, Germany
| | - H C Friederich
- Department of General Internal Medicine and Psychosomatics, Heidelberg University Hospital, 69120, Heidelberg, Germany
| | - J Slaets
- Department of Internal Medicine, Univ Medical Center Groningen, University Groningen, Groningen, Netherlands
| |
Collapse
|
5
|
Schmidt C, Wiedmann F, Beyersdorf C, Zhao Z, El-Battrawy I, Kraft M, Lang S, Szabo G, Karck M, Zhou X, Borggrefe M, Thomas D, Haefeli WE, Decher N, Katus H. 1206Doxapram is a promising new antiarrhythmic drug for an atrial-specific therapy of atrial fibrillation. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
TASK-1 (K2P3.1) is an atrial-specific two-pore domain potassium channel that is significantly upregulated in atrial fibrillation (AF) patients resulting in shortened atrial action potential duration (APD). Inhibition of TASK-1 in human atrial cardiomyocytes reverses AF-related APD shortening to values observed in patients with sinus rhythm (SR). By in silico-modelling and experimental characterization of drug binding sites, doxapram was identified as specific inhibitor of TASK-1.
Purpose
In this study, we investigated the antiarrhythmic efficacy of doxapram in a porcine model of AF to convert and suppress AF.
Methods
We established a new porcine model of persistent AF without induced tachymyopathy. AF was induced in domestic pigs by intermittent atrial burst stimulation using implanted pacemakers. During AF episodes, burst stimulation was inhibited by an integrated pacemaker biofeedback algorithm. AV-node ablation was performed to prevent AF-associated heart failure. All pigs underwent catheter-based electrophysiological investigations prior to and after 14 days doxapram treatment. Pigs in the treatment group received intravenous applications of doxapram twice per day. Rhythm status was continuously recorded by intracardiac long-term ECG monitors. The application of doxapram for cardioversion and long term suppression of AF in pigs with persistent AF was evaluated. Subsequent to the doxapram treatment, porcine cardiomyocytes were isolated from right and left atria and electrophysiologically investigated by patch-clamp and multi-electrode experiments. Atrial electrical remodeling was characterized by analyses of ion channel expression at mRNA and protein levels.
Results
TASK-1 mRNA, protein and transmembrane current were significantly increased in AF pigs compared to SR controls, resulting in shortened atrial APDs. In doxapram-treated AF pigs the AF burden was significantly reduced. After 14 days treatment with doxapram, TASK-1 currents and atrial APDs recorded in porcine cardiomyocytes were reduced and similar to values of SR animals. Doxapram could be successfully applied for cardioversion in pigs with persistent AF. On average, cardioversion was observed 3 minutes after doxapram application.
Conclusion
Doxapram significantly suppressed AF episodes and normalized cellular electrophysiological characteristics in a porcine model of AF through inhibition of the TASK-1 ion channel. Furthermore, doxapram rapidly converted AF into SR in pigs. Therefore, doxapram might serve as a new antiarrhythmic drug to treat AF in patients.
Collapse
Affiliation(s)
- C Schmidt
- University Hospital of Heidelberg, Cardiology, Heidelberg, Germany
| | - F Wiedmann
- University Hospital of Heidelberg, Cardiology, Heidelberg, Germany
| | - C Beyersdorf
- University Hospital of Heidelberg, Cardiology, Heidelberg, Germany
| | - Z Zhao
- University Medical Centre of Mannheim, Mannheim, Germany
| | - I El-Battrawy
- University Medical Centre of Mannheim, Mannheim, Germany
| | - M Kraft
- University Hospital of Heidelberg, Cardiology, Heidelberg, Germany
| | - S Lang
- University Medical Centre of Mannheim, Mannheim, Germany
| | - G Szabo
- University Hospital of Heidelberg, Cardiology, Heidelberg, Germany
| | - M Karck
- University Hospital of Heidelberg, Cardiology, Heidelberg, Germany
| | - X Zhou
- University Medical Centre of Mannheim, Mannheim, Germany
| | - M Borggrefe
- University Medical Centre of Mannheim, Mannheim, Germany
| | - D Thomas
- University Hospital of Heidelberg, Cardiology, Heidelberg, Germany
| | - W E Haefeli
- University Hospital of Heidelberg, Pharmacology, Heidelberg, Germany
| | - N Decher
- Philipps University of Marburg, Physiology, Marburg, Germany
| | - H Katus
- University Hospital of Heidelberg, Cardiology, Heidelberg, Germany
| |
Collapse
|
6
|
Herrmann A, Haefeli WE, Lindemann U, Rapp K, Roigk P, Becker C. [Epidemiology and prevention of heat-related adverse health effects on elderly people]. Z Gerontol Geriatr 2019; 52:487-502. [PMID: 31346679 DOI: 10.1007/s00391-019-01594-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2019] [Accepted: 06/14/2019] [Indexed: 11/25/2022]
Abstract
Heat waves increase the morbidity and mortality in Germany, particularly of older patients in need of care. Due to climate change the number of heat waves in Germany will increase threefold by the end of the century. In addition, the proportion of patients at risk will grow due to demographic change. Therefore, the Government and the Federal States have developed recommendations for heat action plans, in which the medical profession should also participate in the prevention of heat-related damage to health. Physicians and their team should first become acquainted with the topic. In addition, they should inform patients at risk and their relatives of the risks and preventive measures. In the summer a critical check of drugs is also needed because medications impair cooling mechanisms in heat waves, the pharmacokinetics can change and unwanted side effects of drugs occur more frequently. Lastly, due to their central position in the healthcare system, physicians should participate in the coordination of a good nursing care and intensification of social contacts during heat waves.
Collapse
Affiliation(s)
- A Herrmann
- Heidelberger Institut für Global Health, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 130.3, 69120, Heidelberg, Deutschland.
| | - W E Haefeli
- Abteilung Klinische Pharmakologie und Pharmakoepidemiologie, Medizinische Klinik, Universitätsklinikum Heidelberg, Heidelberg, Deutschland
| | - U Lindemann
- Abteilung für Geriatrie und Klinik für Geriatrische Rehabilitation, Robert-Bosch-Krankenhaus, Stuttgart, Deutschland
| | - K Rapp
- Abteilung für Geriatrie und Klinik für Geriatrische Rehabilitation, Robert-Bosch-Krankenhaus, Stuttgart, Deutschland
| | - P Roigk
- Abteilung für Geriatrie und Klinik für Geriatrische Rehabilitation, Robert-Bosch-Krankenhaus, Stuttgart, Deutschland
| | - C Becker
- Abteilung für Geriatrie und Klinik für Geriatrische Rehabilitation, Robert-Bosch-Krankenhaus, Stuttgart, Deutschland
| |
Collapse
|
7
|
Hohls JK, Wild B, Heider D, Brenner H, Böhlen F, Saum KU, Schöttker B, Matschinger H, Haefeli WE, König HH, Hajek A. Association of generalized anxiety symptoms and panic with health care costs in older age-Results from the ESTHER cohort study. J Affect Disord 2019; 245:978-986. [PMID: 30562680 DOI: 10.1016/j.jad.2018.11.087] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/10/2018] [Revised: 10/16/2018] [Accepted: 11/12/2018] [Indexed: 10/27/2022]
Abstract
BACKGROUND Little is known specifically about the association between generalized anxiety symptoms or panic and health care costs in older age. The aim of this study was to examine the association between generalized anxiety symptoms, panic and health care costs in people aged 65 and over. METHODS Cross-sectional data from the 8-year follow-up of a large, prospective cohort study, the ESTHER study, was used. Individuals aged 65 and over, who participated in the study's home assessment, were included in this analysis (n = 2348). Total and sectoral costs were analyzed as a function of either anxiety symptoms, probable panic disorder, or a panic attack, while controlling for selected covariates, using Two Part and Generalized Linear Models. Covariates were chosen based on Andersen's Behavioral Model of Health Care Use. RESULTS There was no significant association between either of the anxiety or panic measures and total health care costs. Stratified by health care sectors, only the occurrence of a panic attack was significantly associated with incurring costs for outpatient non-physician services (OR: 1.99; 95% CI: 1.15-3.45) and inpatient services (OR: 2.14; 95% CI: 1.07-4.28). Other illness-related factors, such as comorbidities and depressive symptoms, were associated with health care costs in several models. LIMITATIONS This was a cross-sectional study relying on self-reported data. CONCLUSION This study points to an association between a panic attack and sector-specific health care costs in people aged 65 and over. Further research, especially using longitudinal data, is needed.
Collapse
Affiliation(s)
- J K Hohls
- Department of Health Economics and Health Services Research, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg 20246, Germany.
| | - B Wild
- Department of General Internal Medicine and Psychosomatics, Heidelberg University Hospital, Heidelberg, Germany
| | - D Heider
- Department of Health Economics and Health Services Research, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg 20246, Germany
| | - H Brenner
- Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany; Network Aging Research, University of Heidelberg, Heidelberg, Germany
| | - F Böhlen
- Department of General Internal Medicine and Psychosomatics, Heidelberg University Hospital, Heidelberg, Germany
| | - K U Saum
- Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany
| | - B Schöttker
- Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany; Network Aging Research, University of Heidelberg, Heidelberg, Germany
| | - H Matschinger
- Department of Health Economics and Health Services Research, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg 20246, Germany; Institute of Social Medicine, Occupational Health and Public Health, University of Leipzig, Germany
| | - W E Haefeli
- Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Germany
| | - H-H König
- Department of Health Economics and Health Services Research, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg 20246, Germany
| | - A Hajek
- Department of Health Economics and Health Services Research, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg 20246, Germany
| |
Collapse
|
8
|
Schaller T, Seyfizadeh N, Exner E, Schnitzler P, Hohmann N, Blank A, Haefeli WE, Krauss J, Arndt M. Herpevizumab, a potent humanized antibody to treat anogenital herpes simplex virus (HSV-1/2) infection – Summary of preclinical data and perspectives of an ongoing clinical trial. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- T Schaller
- Heidelberg ImmunoTherapeutics GmbH, Heidelberg, Deutschland
| | - N Seyfizadeh
- Heidelberg ImmunoTherapeutics GmbH, Heidelberg, Deutschland
| | - E Exner
- Nationales Centrum für Tumorerkrankungen, Medizinische Onkologie, Heidelberg, Deutschland
| | - P Schnitzler
- Universitätsklinikum Heidelberg, Virologische Diagnostik, Heidelberg, Deutschland
| | - N Hohmann
- Nationales Centrum für Tumorerkrankungen, Medizinische Onkologie, Heidelberg, Deutschland
| | - A Blank
- Universitätsklinikum Heidelberg, Klinische Pharmakologie und Pharmakoepidemiologie, Heidelberg, Deutschland
| | - WE Haefeli
- Universitätsklinikum Heidelberg, Klinische Pharmakologie und Pharmakoepidemiologie, Heidelberg, Deutschland
| | - J Krauss
- Nationales Centrum für Tumorerkrankungen, Medizinische Onkologie, Heidelberg, Deutschland
| | - M Arndt
- Heidelberg ImmunoTherapeutics GmbH, Heidelberg, Deutschland
| |
Collapse
|
9
|
Affiliation(s)
| | | | - L Linder
- University Hospital Basel, Switzerland
| | - B Steiner
- F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | | |
Collapse
|
10
|
Blank A, Eidam A, Haag M, Hohmann N, Burhenne J, Schwab M, van de Graaf SFJ, Meyer MR, Maurer HH, Meier K, Weiss J, Bruckner T, Alexandrov A, Urban S, Mikus G, Haefeli WE. The NTCP-inhibitor Myrcludex B: Effects on Bile Acid Disposition and Tenofovir Pharmacokinetics. Clin Pharmacol Ther 2017; 103:341-348. [DOI: 10.1002/cpt.744] [Citation(s) in RCA: 54] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2016] [Revised: 05/10/2017] [Accepted: 05/13/2017] [Indexed: 12/26/2022]
Affiliation(s)
- A Blank
- Department of Clinical Pharmacology and Pharmacoepidemiology; Heidelberg University Hospital; Heidelberg Germany
- German Center for Infection Research (DZIF); Heidelberg Partner Site; Heidelberg Germany
| | - A Eidam
- Department of Clinical Pharmacology and Pharmacoepidemiology; Heidelberg University Hospital; Heidelberg Germany
- German Center for Infection Research (DZIF); Heidelberg Partner Site; Heidelberg Germany
| | - M Haag
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology; University of Tübingen; Stuttgart Germany
- German Center for Infection Research (DZIF); Tübingen Partner Site; Tübingen Germany
| | - N Hohmann
- Department of Clinical Pharmacology and Pharmacoepidemiology; Heidelberg University Hospital; Heidelberg Germany
- German Center for Infection Research (DZIF); Heidelberg Partner Site; Heidelberg Germany
| | - J Burhenne
- Department of Clinical Pharmacology and Pharmacoepidemiology; Heidelberg University Hospital; Heidelberg Germany
- German Center for Infection Research (DZIF); Heidelberg Partner Site; Heidelberg Germany
| | - M Schwab
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology; University of Tübingen; Stuttgart Germany
- German Center for Infection Research (DZIF); Tübingen Partner Site; Tübingen Germany
- Department of Clinical Pharmacology; University Hospital Tübingen; Tübingen Germany
- Department of Pharmacy and Biochemistry; University of Tübingen; Tübingen Germany
| | - SFJ van de Graaf
- Tytgat Institute for Liver and Intestinal Research & Department of Gastroenterology & Hepatology; Academic Medical Center; Amsterdam The Netherlands
| | - MR Meyer
- Department of Clinical Pharmacology and Pharmacoepidemiology; Heidelberg University Hospital; Heidelberg Germany
- Experimental and Clinical Toxicology; Saarland University; Homburg Germany
| | - HH Maurer
- Experimental and Clinical Toxicology; Saarland University; Homburg Germany
| | - K Meier
- Department of Clinical Pharmacology and Pharmacoepidemiology; Heidelberg University Hospital; Heidelberg Germany
- German Center for Infection Research (DZIF); Heidelberg Partner Site; Heidelberg Germany
| | - J Weiss
- Department of Clinical Pharmacology and Pharmacoepidemiology; Heidelberg University Hospital; Heidelberg Germany
- German Center for Infection Research (DZIF); Heidelberg Partner Site; Heidelberg Germany
| | - T Bruckner
- Institute of Medical Biostatistics and Medical Informatics; Heidelberg University Hospital; Heidelberg Germany
| | | | - S Urban
- German Center for Infection Research (DZIF); Heidelberg Partner Site; Heidelberg Germany
- Department of Infectious Diseases, Molecular Virology; Heidelberg University Hospital; Heidelberg Germany
| | - G Mikus
- Department of Clinical Pharmacology and Pharmacoepidemiology; Heidelberg University Hospital; Heidelberg Germany
- German Center for Infection Research (DZIF); Heidelberg Partner Site; Heidelberg Germany
| | - WE Haefeli
- Department of Clinical Pharmacology and Pharmacoepidemiology; Heidelberg University Hospital; Heidelberg Germany
- German Center for Infection Research (DZIF); Heidelberg Partner Site; Heidelberg Germany
| |
Collapse
|
11
|
Send AFJ, Peters-Klimm F, Bruckner T, Haefeli WE, Seidling HM. A randomized controlled trial to assess the effect of a medication plan containing drug administration recommendations on patients' drug knowledge after 2 months. J Clin Pharm Ther 2016; 42:69-74. [PMID: 27796035 DOI: 10.1111/jcpt.12476] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2015] [Accepted: 10/03/2016] [Indexed: 11/27/2022]
Abstract
WHAT IS KNOWN AND OBJECTIVE Patients' drug administration errors are often promoted by poor drug knowledge resulting from inadequate oral or written information. It has previously been shown that a medication plan enhanced with graphical and textual information on drug handling (enhanced medication plan) proved to immediately increase patients' drug knowledge. This study aimed to evaluate the effect of the enhanced medication plan on drug knowledge in outpatients after 2 months (intervention group) compared to patients with a simple medication plan with standard information (control group). METHODS We recruited patients using ≥5 drugs in four family practices in Germany. After inclusion, patients' knowledge on handling of their drugs was assessed using three questions from a standardized catalog. Thereafter, patients were randomized to the intervention or control group. After 2 months, drug knowledge was reassessed with three different questions from the same standardized catalog. RESULTS AND DISCUSSION Of 120 enrolled patients, 75% of participants in the control group (42/60 patients) and 78% of participants in the intervention group (46/60; P = 0·71) completed the study. Baseline drug knowledge was similar in both groups (43·7% vs. 40·6% correct answers). After 2 months, patients' drug knowledge showed an absolute increase of 23·2% in the intervention group (P < 0·01) and was unchanged in the control group (46·0%; P = 0·70). WHAT IS NEW AND CONCLUSION The enhanced medication plan outperformed the effect of a simple medication plan and persistently increased the fraction of correct answers of polypharmacy patients. This demonstrates that the enhanced medication plan may be a useful tool in promoting drug knowledge.
Collapse
Affiliation(s)
- A F J Send
- Cooperation Unit Clinical Pharmacy, Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany
| | - F Peters-Klimm
- Department of General Practice and Health Services Research, University Hospital Heidelberg, Heidelberg, Germany
| | - T Bruckner
- Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany
| | - W E Haefeli
- Cooperation Unit Clinical Pharmacy, Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany
| | - H M Seidling
- Cooperation Unit Clinical Pharmacy, Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany
| |
Collapse
|
12
|
Grünig E, Ohnesorge J, Benjamin N, Burhenne J, Song J, Egenlauf B, Fischer C, Harutyunova S, Huppertz A, Klose H, Haefeli WE. Plasma drug-concentrations in patients with pulmonary arterial hypertension on combination treatment. Pneumologie 2016. [DOI: 10.1055/s-0036-1584623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
13
|
Mayer T, Haefeli WE, Seidling HM. OHP-003 Applying different scales for calculating the patient’s anticholinergic load – five case examples. Eur J Hosp Pharm 2016. [DOI: 10.1136/ejhpharm-2016-000875.391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
14
|
Ohnesorge J, Egenlauf B, Benjamin N, Fischer C, Enderle Y, Burhenne J, Huppertz A, Carls A, Haefeli WE, Grünig E. Change of sildenafil plasma concentrations after transition from bosentan to macitentan in pulmonary arterial hypertension. Pneumologie 2016. [DOI: 10.1055/s-0036-1572030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
15
|
Egenlauf B, Ohnesorge J, Benjamin N, Harutyunova S, Fischer C, Enderle Y, Burhenne J, Nagel C, Huppertz A, Carls A, Haefeli WE, Grünig E. Pharmacokinetic interactions in different combinations of specific pulmonary arterial hypertension treatment. Pneumologie 2016. [DOI: 10.1055/s-0036-1572031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
16
|
Seidling HM, Faller CK, Thalheimer M, Bruckner T, Haefeli WE. [Formal prescribing errors are substantially reduced in electronic prescribing and after teaching sessions]. Dtsch Med Wochenschr 2015; 141:e1-7. [PMID: 26710208 DOI: 10.1055/s-0041-107697] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
INTRODUCTION Prescription forms enable the communication between physicians and pharmacists. Hence, incorrectly issued prescriptions may result in delay of health-care delivery, additional workload, and potentially adverse patient outcomes. We aimed to evaluate the formal prescription quality in our outpatient clinics (OC) before and after performing teaching sessions and using an electronic prescription system to replace handwritten prescriptions. METHODS All OCs of a university hospital were offered a short teaching session on how to issue prescriptions correctly and how to use the electronic prescription system. During four weeks before and after the teaching, we anonymously collected all prescriptions of the OCs in 20 surrounding community pharmacies and assessed whether they were error-free, required an intervention by the pharmacist, additional clarification by the OC, or had to be reissued. RESULTS After the intervention, the absolute fraction of formally error-free prescriptions increased by 12.9% from 52.9% (516/976) to 65.8% (713/1084, p < 0.001; d = 12,9% 95% confidence interval [8,7%; 17,1%]). Largest improvements were seen in prescriptions requiring clarification by the OC (224/976 prescriptions at baseline versus 93/1084 post-intervention, p < 0.001). The fraction of electronic prescriptions increased from 34.9% (341/976) to 46.9% (509/1084, p < 0.001, d = 12,0% 95% confidence interval [7,8%; 16,2%]) with electronic prescriptions consistently being of higher formal quality than handwritten prescriptions. CONCLUSION After increased use of electronic prescribing and teaching courses, formal prescription quality was significantly improved.
Collapse
Affiliation(s)
- H M Seidling
- Abteilung Klinische Pharmakologie und Pharmakoepidemiologie, Universität Heidelberg
| | - C K Faller
- Abteilung Klinische Pharmakologie und Pharmakoepidemiologie, Universität Heidelberg
| | - M Thalheimer
- Qualitätsmanagement / Medizincontrolling, Universitätsklinikum Heidelberg
| | - T Bruckner
- Institut für Medizinische Biometrie und Informatik Universität Heidelberg
| | - W E Haefeli
- Abteilung Klinische Pharmakologie und Pharmakoepidemiologie, Universität Heidelberg
| |
Collapse
|
17
|
Hajek A, Bock JO, Brenner H, Saum KU, Matschinger H, Haefeli WE, Quinzler R, Heider D, König HH. [Which Factors Affect Out-of-pocket Payments for Health Care Services Among Elderly Germans? Results of a Longitudinal Study]. Gesundheitswesen 2015; 79:e18-e25. [PMID: 26551845 DOI: 10.1055/s-0035-1564247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Background: In Germany, out-of-pocket payments (OOPP) account for a large proportion of total health expenditure. However, there are only few investigations on how morbidity-related, sociodemographic and lifestyle factors affect OOPP particularly in the older population. The aim of this study was to identify factors affecting OOPP for health care services among elderly Germans in a longitudinal setting. Methods: This longitudinal study used data from 2 follow-up waves (3-year interval) from a population-based prospective cohort study (ESTHER study) collected in Saarland, Germany. At the first follow-up wave, subjects were between 57 and 84 years old. Participants provided comprehensive data including individual OOPP for the preceding 3 months. Fixed effects (FE) regressions were used to determine factors affecting OOPP. Results: Mean individual OOPP (3-month period) rose from € 119 (first wave) to € 136 (second wave). Longitudinal regressions showed that higher morbidity did not affect OOPP. Moreover, changes in sociodemographic as well as lifestyle factors were not related to changes in OOPP. Solely, exemption of OOPP reduced the dependent variable significantly. Conclusion: In contrast to cross-sectional findings for Germany, OOPP are not related to morbidity and income in this study. This underlines the complex nature of OOPP in old age and the need for longitudinal studies to gain some insight into the underlying causal factors.
Collapse
Affiliation(s)
- A Hajek
- Institut für Gesundheitsökonomie und Versorgungsforschung, Universitätsklinikum Hamburg-Eppendorf, Hamburg
| | - J-O Bock
- Institut für Gesundheitsökonomie und Versorgungsforschung, Universitätsklinikum Hamburg-Eppendorf, Hamburg
| | - H Brenner
- Klinische Epidemiologie und Alternsforschung, Deutsches Krebsforschungszentrum, Heidelberg
| | - K-U Saum
- Klinische Epidemiologie und Alternsforschung, Deutsches Krebsforschungszentrum, Heidelberg
| | - H Matschinger
- Institut für Gesundheitsökonomie und Versorgungsforschung, Universitätsklinikum Hamburg-Eppendorf, Hamburg
| | - W E Haefeli
- Klinische Pharmakologie und Pharmakoepidemiologie, Universität Heidelberg, Heidelberg
| | - R Quinzler
- Klinische Pharmakologie und Pharmakoepidemiologie, Universität Heidelberg, Heidelberg
| | - D Heider
- Institut für Gesundheitsökonomie und Versorgungsforschung, Universitätsklinikum Hamburg-Eppendorf, Hamburg
| | - H-H König
- Institut für Gesundheitsökonomie und Versorgungsforschung, Universitätsklinikum Hamburg-Eppendorf, Hamburg
| |
Collapse
|
18
|
Freytag A, Quinzler R, Freitag M, Bickel H, Fuchs A, Hansen H, Hoefels S, König HH, Mergenthal K, Riedel-Heller SG, Schön G, Weyerer S, Wegscheider K, Scherer M, van den Bussche H, Haefeli WE, Gensichen J. [Use and potential risks of over-the-counter analgesics]. Schmerz 2015; 28:175-82. [PMID: 24718747 DOI: 10.1007/s00482-014-1415-5] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
BACKGROUND AND AIM We investigated the use of prescription and non-prescription (over-the-counter, OTC) analgesics and the associated risks in elderly patients with multiple morbidities. METHODS Pain medication use was evaluated from the baseline data (2008/2009) of the MultiCare cohort enrolling elderly patients with multiple morbidities who were treated by primary care physicians (trial registration: ISRCTN89818205). We considered opioids (N02A), other analgesics, and antipyretics (N02B) as well as nonsteroidal anti-inflammatory drugs (NSAIDs; M01A). OTC use, duplicate prescription, dosages, and interactions were examined for acetylsalicylic acid, diclofenac, (dex)ibuprofen, naproxen, and acetaminophen. RESULTS Of 3,189 patients with multiple morbidities aged 65-85 years, 1,170 patients reported to have taken at least one prescription or non-prescription analgesic within the last 3 months (36.7 %). Of these, 289 patients (24.7 % of 1,170) took at least one OTC analgesic. Duplicate prescription was observed in 86 cases; 15 of these cases took the analgesics regularly. In two cases, the maximum daily dose of diclofenac was exceeded due to duplicate prescription. In 235 cases, patients concurrently took a drug with a potentially clinically relevant interaction. In 43 cases (18.3 % of 235) an OTC analgesic, usually ibuprofen, was involved. DISCUSSION About one third of the elderly patients took analgesics regularly or as needed. Despite the relatively high use of OTC analgesics, the proportions of duplicate prescription, medication overdoses, and adverse interactions due to OTC products was low.
Collapse
Affiliation(s)
- A Freytag
- Institut für Allgemeinmedizin, Universitätsklinikum, Friedrich-Schiller-Universität, Bachstr. 18, 07743, Jena, Deutschland
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Send AFJ, Haefeli WE, Seidling HM. DI-040 Long-term effect of an individualised medication plan with drug administration recommendations on the patients’ drug knowledge. Eur J Hosp Pharm 2015. [DOI: 10.1136/ejhpharm-2015-000639.216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
20
|
Lampert A, Haefeli WE, Seidling HM. DI-035 Should we make patients and nurses aware of their drug administration problems and training needs? Eur J Hosp Pharm 2015. [DOI: 10.1136/ejhpharm-2015-000639.211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
21
|
Lohmann K, Gartner D, Kurze R, Schösler T, Schwald M, Störzinger D, Hoppe-Tichy T, Haefeli WE, Seidling HM. More than just crushing: a prospective pre-post intervention study to reduce drug preparation errors in patients with feeding tubes. J Clin Pharm Ther 2015; 40:220-5. [PMID: 25655434 DOI: 10.1111/jcpt.12250] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2014] [Accepted: 01/12/2015] [Indexed: 11/28/2022]
Abstract
WHAT IS KNOWN AND OBJECTIVES Incorrect drug preparation for patients with feeding tubes can result in harm for the patient and the preparing person. Combined intervention programs are effective tools to reduce such preparation errors. However, to date, intervention programs have been mostly tested in hospitals with computerized physician order entry (CPOE), unit-dose systems, or ward-based clinical pharmacists. Hence, the primary objective of this study was to develop and evaluate an intervention program tailored to hospitals without such preconditions. METHODS We conducted a prospective pre-/post-intervention study on a gastroenterological intensive care unit (ICU) and a surgical ward for oral, dental and maxillofacial diseases (surgical ward). During the study periods, observers documented and evaluated drug preparation processes of all peroral drugs for patients with feeding tubes. The primary endpoint was the rate of inappropriately crushed and/or suspended solid peroral drugs in regards to all solid peroral drugs. RESULTS AND DISCUSSION Altogether, we evaluated 775 drug preparation processes of solid peroral drugs on the ICU and 975 on the surgical ward. The intervention program significantly reduced incorrect crushing and/or suspending of solid peroral drugs for administration to patients with feeding tubes from 9·8% to 4·2% (P < 0·01) on the ICU and from 5·7% to 1·4% (P < 0·01) on the surgical ward. WHAT IS NEW AND CONCLUSION The implementation of the newly developed intervention program significantly reduced the rate of inappropriately prepared solid peroral drugs, suggesting that it is an effective measure to enable safe drug administration for inpatients with feeding tubes.
Collapse
Affiliation(s)
- K Lohmann
- Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany; Cooperation Unit Clinical Pharmacy, University of Heidelberg, Heidelberg, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Ammenwerth E, Aly AF, Bürkle T, Christ P, Dormann H, Friesdorf W, Haas C, Haefeli WE, Jeske M, Kaltschmidt J, Menges K, Möller H, Neubert A, Rascher W, Reichert H, Schuler J, Schreier G, Schulz S, Seidling HM, Stühlinger W, Criegee-Rieck M. Memorandum on the use of information technology to improve medication safety. Methods Inf Med 2014; 53:336-43. [PMID: 24902537 DOI: 10.3414/me14-01-0040] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2014] [Accepted: 05/01/2014] [Indexed: 12/12/2022]
Abstract
BACKGROUND Information technology in health care has a clear potential to improve the quality and efficiency of health care, especially in the area of medication processes. On the other hand, existing studies show possible adverse effects on patient safety when IT for medication-related processes is developed, introduced or used inappropriately. OBJECTIVES To summarize definitions and observations on IT usage in pharmacotherapy and to derive recommendations and future research priorities for decision makers and domain experts. METHODS This memorandum was developed in a consensus-based iterative process that included workshops and e-mail discussions among 21 experts coordinated by the Drug Information Systems Working Group of the German Society for Medical Informatics, Biometry and Epidemiology (GMDS). RESULTS The recommendations address, among other things, a stepwise and comprehensive strategy for IT usage in medication processes, the integration of contextual information for alert generation, the involvement of patients, the semantic integration of information resources, usability and adaptability of IT solutions, and the need for their continuous evaluation. CONCLUSION Information technology can help to improve medication safety. However, challenges remain regarding access to information, quality of information, and measurable benefits.
Collapse
Affiliation(s)
- E Ammenwerth
- Elske Ammenwerth, Institute of Health Informatics, University for Health Sciences, Medical Informatics and Technology (UMIT), Eduard Wallnöfer-Zentrum 1, 6060 Hall in Tirol, Austria, E-mail:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Carls A, Springer W, Arnold R, Winter J, Gorenflo M, Haefeli WE. Substantial Increase of Sildenafil Bioavailability after Sublingual Administration in Two Children with Congenital Heart Defects. Thorac Cardiovasc Surg 2013. [DOI: 10.1055/s-0033-1354504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
24
|
Seidling HM, Kaltschmidt J, Ammenwerth E, Haefeli WE. Medication safety through e-health technology: can we close the gaps? Br J Clin Pharmacol 2013; 76 Suppl 1:i-iv. [PMID: 24007455 PMCID: PMC3781675 DOI: 10.1111/bcp.12217] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
|
25
|
Bates DW, Baysari MT, Dugas M, Haefeli WE, Kushniruk AW, Lehmann CU, Liu J, Mantas J, Margolis A, Miyo K, Nohr C, Peleg M, de Quirós FGB, Slight SP, Starmer J, Takabayashi K, Westbrook JI. Discussion of "Attitude of physicians towards automatic alerting in computerized physician order entry systems". Methods Inf Med 2013; 52:109-127. [PMID: 23508343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
With these comments on the paper "Attitude of Physicians Towards Automatic Alerting in Computerized Physician Order Entry Systems", written by Martin Jung and co-authors, with Dr. Elske Ammenwerth as senior author [1], the journal wants to stimulate a broad discussion on computerized physician order entry systems. An international group of experts have been invited by the editor of Methods to comment on this paper. Each of the invited commentaries forms one section of this paper.
Collapse
Affiliation(s)
- D W Bates
- Centre for Patient Safety Research and Practice, Division of General Internal Medicine and Primary Care, Brigham and Women’s Hospital, Boston, Massachusetts 02120, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Mahler C, Jank S, Pruszydlo MG, Hermann K, Gärtner H, Kaltschmidt J, Ludt S, Bertsche T, Haefeli WE, Szecsenyi J. [HeiCare®: a project aiming to improve medication communication across health care sectors]. Dtsch Med Wochenschr 2011; 136:2239-44. [PMID: 22028288 DOI: 10.1055/s-0031-1292036] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Abstract
BACKGROUND AND OBJECTIVE Changes between health care sectors represent a critical phase in long-term pharmacotherapy. The aim of the Hei CARE(®) project was to close the communication gap at the interface between primary care physicians (PCP), hospital physicians and patients, and to improve quality and safety of pharmacotherapy. METHODS Physicians who enrolled patients with long-term pharmacotherapy were able to participate in the Hei CARE(®) project. After enrolment the patient's medication was entered in the internet-based medication knowledge data base AiD PRAXIS and checked for medication interactions and optimized if necessary. At hospitalisation medication was transferred electronically to the hospital (AiD KLINIK(®)) and on discharge integrated in the discharge letter and faxed to the primary care physician (PCP). The project was evaluated using quantitative and qualitative methods. Hei CARE(®) -cases, in which medication was transferred electronically as planned, were compared with the other cases. PCPs' experiences were collected in focus groups. RESULTS One thousand and three chronically ill patients of 56 primary care practices participated. 259 patients were hospitalized between October 2005 and March 2009 of which entrance and discharge medication were transferred both ways via the electronic prescribing platform in 67 cases. The number of changes in medication was reduced in comparison to the other cases. Participating PCPs reported positive changes through Hei CARE(®) as well as further potential for optimizing communication across health care sectors. CONCLUSION Use of a common internet-based medication knowledge data base (Hei CARE(®) ) in both health care sectors reduced the number of changes in pharmacotherapy. Seamless care in chronically ill patients was thereby improved. The project also demonstrated that improving communication across health care sectors is a slow process.
Collapse
Affiliation(s)
- C Mahler
- Universitätsklinikum Heidelberg, Abteilung Allgemeinmedizin und Versorgungsforschung
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Katzenmaier S, Markert C, Riedel KD, Burhenne J, Haefeli WE, Mikus G. Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy. Clin Pharmacol Ther 2011; 90:666-73. [PMID: 21937987 DOI: 10.1038/clpt.2011.164] [Citation(s) in RCA: 99] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
We established a new limited sampling strategy to assess CYP3A activity and evaluated the time course of reversible (voriconazole) and irreversible (ritonavir) CYP3A inhibition. In this randomized trial, two groups, each with eight healthy participants, received CYP3A inhibitors voriconazole or ritonavir orally for 9 days, with 3 mg midazolam (MDZ) administered before the inhibitor treatment, on days 1, 2, 3, 5, 8, and 9 during inhibitor treatment, and on days 10, 11, and 12 (3 days) after discontinuation. Plasma MDZ area under the curve (AUC) between 2 and 4 h after oral administration in the form of a solution strongly correlated with MDZ clearance. Using this parameter, maximum inhibition of voriconazole and ritonavir was calculated to have occurred only 48 h after starting of the inhibitor (percentage of baseline MDZ clearance, voriconazole: 10.6%; ritonavir: 8.4%). Recovery of CYP3A activity occurred with a half-life of 24 h after voriconazole, whereas ritonavir inhibition was still strong 3 days after discontinuation. These findings underscore the substantial and gradual alterations in dose requirements in the first days of and after such combination therapies.
Collapse
Affiliation(s)
- S Katzenmaier
- Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University, Heidelberg, Germany
| | | | | | | | | | | |
Collapse
|
28
|
Yimer G, Amogne W, Habtewold A, Makonnen E, Ueda N, Suda A, Worku A, Haefeli WE, Burhenne J, Aderaye G, Lindquist L, Aklillu E. High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study. Pharmacogenomics J 2011; 12:499-506. [DOI: 10.1038/tpj.2011.34] [Citation(s) in RCA: 90] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
29
|
Ngaimisi E, Mugusi S, Minzi O, Sasi P, Riedel KD, Suda A, Ueda N, Janabi M, Mugusi F, Haefeli WE, Bertilsson L, Burhenne J, Aklillu E. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. Clin Pharmacol Ther 2011; 90:406-13. [PMID: 21814190 DOI: 10.1038/clpt.2011.129] [Citation(s) in RCA: 66] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
We performed a prospective comparative study to examine, from a pharmacogenetics perspective, the effect of rifampicin (RIF) on long-term efavirenz (EFV) autoinduction and kinetics. In a study population of patients with HIV receiving EFV with RIF (arm 2, n = 54) or without RIF (arm 1, n = 128 controls), intraindividual and interindividual plasma EFV and 8-hydroxyefavirenz levels were compared at weeks 4 and 16 of EFV therapy. In arm 2, RIF was initiated 4 weeks before starting EFV. In controls (arm 1), the plasma EFV was significantly lower whereas 8-hydroxyefavirenz was higher at week 16 as compared to week 4. By contrast, there were no significant differences in plasma EFV and 8-hydroxyefavirenz concentrations over time in arm 2. At week 4, the plasma EFV concentration was significantly lower in arm 2 as compared to arm 1, but no significant differences were observed by week 16. When stratified by CYP2B6 genotype, significant differences were observed only with respect to CYP2B6*1/*1 genotypes. Ours is the first report of the CYP2B6 genotype-dependent effect of RIF on long-term EFV autoinduction.
Collapse
Affiliation(s)
- E Ngaimisi
- Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska University Hospital-Huddinge, Karolinska Institute, Stockholm, Sweden
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Senger C, Seidling HM, Quinzler R, Leser U, Haefeli WE. Design and evaluation of an ontology-based drug application database. Methods Inf Med 2010; 50:273-84. [PMID: 21057721 DOI: 10.3414/me10-01-0013] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2010] [Accepted: 06/02/2010] [Indexed: 11/09/2022]
Abstract
OBJECTIVES Several recently published cases of preventable adverse drug reactions were associated with flaws in drug application. However, current clinical decision support (CDS) systems do not properly consider drug application issues and thus do not support effective prevention of such medication errors. With the aim to improve CDS in this respect, we developed a comprehensive model precisely describing all aspects of drug application. METHODS The model consists of 1) a schema comprising all relevant attributes of drug application and 2) an ontology providing a hierarchically structured vocabulary of terms that describe the possible values of the schema's attributes. Finally, medical products were annotated by a semi-automatic term assignment process. For evaluation, we developed an algorithm that uses our model to compute a meaningful similarity between medicinal products with respect to their drug application characteristics. RESULTS Our schema consists of 22 attributes. The ontology contains 248 terms, textual descriptions, and synonym lists. More than 58,700 medicinal products were automatically annotated with >386,600 terms. 2,450 drugs were manually reviewed by experts, adding >4500 terms. The annotation and similarity measure allow for (similarity) searches, clustering, and proper discrimination of drugs with different drug application characteristics. We demonstrated the value of our approach by means of a set of case studies. CONCLUSION Our model enables a detailed description of drug application, allowing for semantically meaningful comparisons of drugs. This is an important prerequisite for improving the ability of CDS systems to prevent prescription errors.
Collapse
Affiliation(s)
- C Senger
- Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
| | | | | | | | | |
Collapse
|
31
|
Ngaimisi E, Mugusi S, Minzi OM, Sasi P, Riedel KD, Suda A, Ueda N, Janabi M, Mugusi F, Haefeli WE, Burhenne J, Aklillu E. Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin Pharmacol Ther 2010; 88:676-84. [PMID: 20881953 DOI: 10.1038/clpt.2010.172] [Citation(s) in RCA: 89] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
We investigated the influence of gender and pharmacogenetic variations on long-term efavirenz autoinduction and disposition among patients with HIV in Tanzania (N = 129). Plasma concentrations (at 16 h) of efavirenz and 8-hydroxyefavirenz were quantified at weeks 4 and 16 of therapy. Genotyping was performed to identify cytochrome P450 (CYP) 2B6*6, CYP3A5*3, *6, and *7, and ABCB1-3435 C/T genotypes. There were reductions in the median efavirenz concentration (Wilcoxon matched-pair test P < 0.001) and efavirenz/8-hydroxyefavirenz ratio (P < 0.001) by 19 and 32%, respectively, at week 16 as compared with week 4. The proportion of patients with efavirenz concentration <1 µg/ml at week 16 was higher by 67, 25, and 5% in CYP2B6*1/*1, *1/*6, and *6/*6 genotypes, respectively. The defined therapeutic range based on observed plasma concentrations is affected by the time point of sampling and the CYP2B6 genotype. The effect of efavirenz autoinduction on reducing plasma exposure continues up to week 16 and predominantly affects CYP2B6 extensive metabolizers. Among CYP2B6 slow metabolizers, the presence of a CYP3A5 genotype allele is associated with greater effects of efavirenz autoinduction on plasma concentrations of the drug. The cumulative induction may influence the long-term antiretroviral therapy outcome, particularly in CYP2B6*1 carriers.
Collapse
Affiliation(s)
- E Ngaimisi
- Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska University Hospital-Huddinge, Karolinska Institute, Stockholm, Sweden
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Ghofrani H, Distler O, Gerhardt F, Gorenflo M, Grünig E, Haefeli W, Held M, Hoeper M, Kähler CM, Kaemmerer H, Klose H, Köllner V, Kopp B, Mebus S, Meyer A, Miera O, Pittrow D, Riemekasten G, Rosenkranz S, Schranz D, Voswinckel R, Olschewski H. Therapie der pulmonal arteriellen Hypertonie (PAH). Dtsch Med Wochenschr 2010; 135 Suppl 3:S87-101. [DOI: 10.1055/s-0030-1263316] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
33
|
Seidling HM, Schmitt SPW, Bruckner T, Kaltschmidt J, Pruszydlo MG, Senger C, Bertsche T, Walter-Sack I, Haefeli WE. Patient-specific electronic decision support reduces prescription of excessive doses. Qual Saf Health Care 2010; 19:e15. [PMID: 20427312 DOI: 10.1136/qshc.2009.033175] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
OBJECTIVES Prescription of excessive doses is the most common prescription error, provoking dose-dependent adverse drug reactions. Clinical decision support systems (CDSS) can prevent prescription errors especially when mainly clinically relevant warnings are issued. We have built and evaluated a CDSS providing upper dose limits personalised to individual patient characteristics thus guaranteeing for specific warnings. METHODS For 170 compounds, detailed information on upper dose limits (according to the drug label) was compiled. A comprehensive software-algorithm extracted relevant patient information from the electronic chart (eg, age, renal function, comedication). The CDSS was integrated into the local prescribing platform for outpatients and patients at discharge, providing immediate dosage feedback. Its impact was evaluated in a 90-day intervention study (phase 1: baseline; phase 2: intervention). Outcome measures were frequency of excessive doses before and after intervention considering potential induction of new medication errors. Moreover, predictors for alert adherence were analysed. RESULTS In phase 1, 552 of 12,197 (4.5%) prescriptions exceeded upper dose limits. In phase 2, initially 559 warnings were triggered (4.8%, p=0.37). Physicians were responsive to one in four warnings mostly adjusting dosages. Thus, the final prescription rate of excessive doses was reduced to 3.6%, with 20% less excessive doses compared with baseline (p<0.001). No new manifest prescription errors were induced. Physicians' alert adherence correlated with patients' age, prescribed drug class, and reason for the alert. CONCLUSION During the 90-day study, implementation of a highly specific algorithm-based CDSS substantially improved prescribing quality with a high acceptance rate compared with previous studies.
Collapse
Affiliation(s)
- H M Seidling
- Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, Heidelberg 69120, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Bertsche T, Bertsche A, Krieg EM, Kunz N, Bergmann K, Hanke G, Hoppe-Tichy T, Ebinger F, Haefeli WE. Prospective pilot intervention study to prevent medication errors in drugs administered to children by mouth or gastric tube: a programme for nurses, physicians and parents. Qual Saf Health Care 2010; 19:e26. [PMID: 20378618 DOI: 10.1136/qshc.2009.033753] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BACKGROUND Drug administration in children is an error-prone task for nurses and parents because individual dose adjustment is often necessary, and suitable formulations for children are frequently lacking. Hence, in the absence of measures for their prevention, medication errors are likely to occur. OBJECTIVE To assess the error prevalence in drug administration by mouth or gastric tube before and after implementing a programme for quality improvement for nurses and parents. DESIGN, SETTING AND PARTICIPANTS Prospective, two-period cohort intervention study on a paediatric neurology ward of a university hospital where drug administration procedures of nurses and parents were consecutively monitored during the routine drug administration hours. MAIN OUTCOMES MEASURE Prevalence of administration errors before and after implementing instructions for appropriate drug administration, and a teaching and training programme supported by information pamphlets. RESULTS Altogether, 1164 predefined administration tasks were assessed, 675 before and 489 after the intervention. Of these, 95.7% (after the INTERVENTION 92.6%) were performed by nurses. Errors addressed by the intervention were reduced from 261/646 tasks (40.4%) to 36/453 (7.9%, p<0.001) in nurses and from 28/29 (96.6%) to 2/36 (5.6%, p<0.001) in parents. Errors in predefined categories concerning tablet dissolution, tablet storage, oral liquids, tablet splitting, administration by gastric tube and others were all considerably less frequent after the intervention (each p<0.001). CONCLUSION Errors of drug administration by mouth and gastric tube represent a considerable and often neglected drug-related problem in paediatric inpatients. Targeted quality-improvement programmes can substantially and rapidly reduce error prevalence. Appropriate teaching and training of both nurses and parents supported by pamphlets was a highly efficient way to reduce error prevalence.
Collapse
Affiliation(s)
- T Bertsche
- Department of Clinical Pharmacology and Pharmacoepidemiology, INF 410, 69120 Heidelberg, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Hafner V, Jäger M, Matthée AK, Ding R, Burhenne J, Haefeli WE, Mikus G. Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity. Clin Pharmacol Ther 2009; 87:191-6. [PMID: 19924124 DOI: 10.1038/clpt.2009.206] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
We aimed to assess the effect of coadministration and withdrawal of a potent cytochrome P450 3A (CYP3A) inhibitor (ritonavir) and a potent CYP3A inducer (St John's wort) on CYP3A enzyme activity in an open, fixed-sequence study design. We investigated the pharmacokinetics of midazolam: (i) at baseline, (ii) after a single dose of either St John's wort or ritonavir (each n = 6), (iii) after 14 days of coadministration of ritonavir (300 mg b.i.d.) and St John's wort (300 mg t.i.d.), and (iv) at 2 days after cessation of both St John's wort and ritonavir. Combined administration of inducer and inhibitor resulted in a predominance of enzyme inhibition: coadministration of St John's wort and ritonavir with intravenous administration of midazolam resulted in an increase in the area under the plasma concentration-time curve (AUC)(0-8 h) of midazolam to 180% of baseline value, whereas with orally administered midazolam, the AUC(0-6 h) increased to 412% of baseline value (P < 0.05 for each). After cessation of the coadministered drugs, the AUC(0-6 h) of orally administered midazolam decreased to 6% of the level observed during combined administration, and the AUC(0-8 h) of intravenously administered midazolam decreased to 33% of the values observed during combined administration (P < 0.001 for each). Induction may be unmasked after the withdrawal of a combination of a potent CYP3A inhibitor and a potent CYP3A inducer, leading to substantial drops in drug exposure of CYP3A substrates. This may require substantial dose adjustments, particularly of orally administered drugs.
Collapse
Affiliation(s)
- V Hafner
- Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany
| | | | | | | | | | | | | |
Collapse
|
36
|
Mahler C, Jank S, Hermann K, Haefeli WE, Szecsenyi J. [Information on medications - How do chronically ill patients assess counselling on drugs in general practice?]. Dtsch Med Wochenschr 2009; 134:1620-4. [PMID: 19650022 DOI: 10.1055/s-0029-1233990] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
BACKGROUND AND OBJECTIVE Patients with chronic disease have to rely on safe and efficacious drug treatment. They therefore need individual information on their medicaton, in which counselling within the setting of general practice plays a pivotal role. However, information that seems to be relevant from the doctor's point of view is not necessarily consistent with the information patients consider to be necessary. The question was addressed in this study on to what extent patients are satisfied with the information they have received on their medication in general practice? METHODS A standardized questionnaire consisting of the SIMS-D (German version of the Satisfaction with Information about Medicines Scale) and MARS-D (German version of the Medication Adherence Report Scale) was sent to 834 chronically ill patients between March 2007 and April 2008. RESULTS Patients felt quite satisfied with the information they received on "action and usage" of medication (mean 6.95; range 0 - 9). They were not quite so satisfied with the information they received on "potential problems of medication". Self-reported adherence showed a high mean of 23.6 (range 5 - 25). Less than half of the doctors (43.6 %) inquired "always" or "often" whether patients were taking any other drugs than those prescribed. CONCLUSION Patients wish to have more information on potential drug-related problems. More attention needs to be given to a structured review of drugs prescribed in general practice.
Collapse
Affiliation(s)
- Cornelia Mahler
- Universitätsklinikum Heidelberg, Abteilung Allgemeinmedizin und Versorgungsforschung, Heidelberg.
| | | | | | | | | |
Collapse
|
37
|
Bertsche T, Kaltschmidt J, Haefeli WE. [Patient safety based on computer-assisted drug therapy. Electronic check-up of the patient]. Internist (Berl) 2009; 50:748-56. [PMID: 19430754 DOI: 10.1007/s00108-009-2398-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Patients in internal medicine frequently experience adverse drug events. Many of those events, however, are avoidable because they are caused by medication errors, which are particularly frequent in drug prescribing. Therefore, practical concepts are needed to make the rapidly growing knowledge on drugs available already during prescription. But also when deviations from standards are intended access to up-to-date information is required. Computer-based systems can offer support for prescribing clinicians to meet these claims and thus improve the quality of pharmacotherapy. To reach this goal, such systems have to be interlinked among each other and with systems of primary, secondary, and tertiary care. They must be based on scientific published evidence and should consider as many factors as possible for individualization of drug therapy. Individualization and focusing on relevant information are prerequisites to prevent inappropriate alerts (over-alerting) and thus to increase acceptance in practical use.
Collapse
Affiliation(s)
- T Bertsche
- Abteilung Innere Medizin VI, Klinische Pharmakologie und Pharmakoepidemiologie, Universitätsklinikum Heidelberg
| | | | | |
Collapse
|
38
|
Haefeli W. Medizinische Probleme und
Risiken bei der rabattvertragsgerechten Umstellung von
Inhalatoren in Deutschland – Erwiderung. Dtsch Med Wochenschr 2008. [DOI: 10.1055/s-0028-1082817] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
39
|
Pruszydlo MG, Quinzler R, Kaltschmidt J, Haefeli WE. [Medical problems and risks of switching drugs according to legal requirements of drug discount contracts in Germany]. Dtsch Med Wochenschr 2008; 133:1423-8. [PMID: 18592450 DOI: 10.1055/s-2008-1081094] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
INTRODUCTION Since 2007 German health insurance funds may conclude discount contracts with pharmaceutical companies for individual drugs. According to German legislation pharmacies are liable to preferentially dispense these drugs to patients of the respective funds if the prescribed drug is identical regarding active ingredient, strength, package size, and route of administration, and is approved for the same indication. We aimed to assess the number and nature of clinically relevant differences between prescribed drug and its legal alternatives. METHODS Using databases and expert systems of the drug information system AiD KLINIK we evaluated all 258 412 exchangeable drug pairs of the German market currently regulated by discount contracts. RESULTS 15,7 % of the drug pairs differed in dosage, in one quarter each colour or shape was significantly different, and in roughly 3 % the size of the substituted drug differed by more than 50 %. In 9,43 % splitting characteristics of solid oral doses differed and in 1,87 % the substituted drug contained additives with allergenic potential not present in the primarily selected drug. On average 0,44 clinically relevant differences could be calculated in each substitution. CONCLUSION This study has revealed that current legal provision ignore important medical criteria of the substitution process including individual risks (e. g. allergies). Patients will have to change the drug application process and will therefore need appropriate information and training. All these differences between substitutional drug pairs should already be known when prescribing so as to maintain patient safety in the face of this merely cost-saving measure.
Collapse
Affiliation(s)
- M G Pruszydlo
- Klinische Pharmakologie und Pharmakoepidemiologie, Abteilung Innere Medizin VI, Universitätsklinikum Heidelberg, Heidelberg, Deutschland
| | | | | | | |
Collapse
|
40
|
Quinzler R, Schmitt SPW, Szecsenyi J, Haefeli WE. Optimizing information on drug exposure by collection of package code information in questionnaire surveys. Pharmacoepidemiol Drug Saf 2007; 16:1024-30. [PMID: 17457950 DOI: 10.1002/pds.1406] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
PURPOSE The thorough analysis of special drug characteristics requires information on the specific brand of a drug. This information is often not sought in pharmacoepidemiologic surveys although in many countries packages are labelled with an unequivocal code (in Germany called Pharmazentralnummer (PZN)). We aimed to assess the benefit and quality of PZN information collected in self-completed questionnaires. METHODS We performed a survey in 905 ambulatory patients who were asked to list brand name, strength, and the PZN of all drugs they were taking. RESULTS The medication list was completed by 97.5% (n = 882) of the responding patients (mean age 67.3 years). Altogether 5543 drugs (100%) were mentioned in the questionnaires and for 4230 (76.3%) the exact drug package could be allocated on the basis of the PZN. When PZN was considered in addition to the drug name the quality of drug coding was significantly improved (p < 0.001) with regard to the allocation of drug package (74% versus 2%), brand (90% versus 70%), and strength (96% versus 86%). The time needed for drug coding was three times shorter. CONCLUSIONS The high response rate and high fraction of correct PZN indicate that the collection of package code information is a valuable method to achieve more accurate drug data in questionnaire surveys and to facilitate the drug coding procedure.
Collapse
Affiliation(s)
- R Quinzler
- Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany
| | | | | | | |
Collapse
|
41
|
Rengelshausen J, Göggelmann C, Burhenne J, Riedel KD, Mikus G, Walter-Sack I, Haefeli WE. Reduction in non-glomerular renal clearance of the caffeine metabolite 1-methylxanthine by probenecid. Int J Clin Pharmacol Ther 2007; 45:431-7. [PMID: 17725176 DOI: 10.5414/cpp45431] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
OBJECTIVE Urinary caffeine metabolic ratios used to quantify the activity of numerous drug-metabolizing enzymes are an established component of cocktail approaches for metabolic phenotyping. Because in vitro evidence suggests that 1-methylxanthine (1-MX), a major caffeine metabolite, is actively secreted into urine by organic anion transporters (hOATs), coadministration of renal hOAT inhibitors like probenecid may impair these procedures. METHODS In a randomized, placebo-controlled, double-blind crossover design, single oral doses of 300 mg caffeine with oral coadministration of placebo or 500 mg probenecid 3 times daily for 2 days were administered to 7 healthy men. The plasma and urine concentrations of caffeine and its major metabolites 1,7-dimethylxanthine (1,7-DMX) and 1-MX were determined by high-performance liquid chromatography. RESULTS Coadministration of probenecid resulted in a 34% reduction of the renal clearance of 1-MX (mean +/- SD 190 +/- 42 versus 290 +/- 83 ml min(-1), 95% CI on difference 0.2, 200, p = 0.04) with a 41% reduction in its estimated non-glomerular clearance. The renal clearances of caffeine and 1,7-DMX and the area under the plasma concentration-time curves of all substances were not significantly changed. CONCLUSIONS 1-MX undergoes renal tubular secretion which is substantially reduced by probenecid, possibly due to inhibition of renal hOATs. This inhibition may explain the influence of probenecid on urinary caffeine metabolic ratios and, thus, its impact on the assessment of enzyme activities. It also suggests that 1-MX might serve as a model substrate for the renal tubular transport of organic anions.
Collapse
Affiliation(s)
- J Rengelshausen
- Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany
| | | | | | | | | | | | | |
Collapse
|
42
|
|
43
|
Seidling HM, Al Barmawi A, Kaltschmidt J, Bertsche T, Pruszydlo MG, Haefeli WE. Detection and prevention of prescriptions with excessive doses in electronic prescribing systems. Eur J Clin Pharmacol 2007; 63:1185-92. [PMID: 17786416 DOI: 10.1007/s00228-007-0370-9] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2007] [Accepted: 08/07/2007] [Indexed: 01/26/2023]
Abstract
INTRODUCTION Dose dependent adverse drug reactions are often caused by prescribing errors ignoring upper dose limits. Thus, computerised physician order entry incorporating maximum recommended therapeutic doses (MRTDs) might reduce prescriptions of excessive doses. We evaluated the suitability of MRTD information as published in the Summary of Product Characteristics (SPC) (MRTD(SPC)) or by the US Food and Drug Administration (MRTD(FDA)) and the value of Defined Daily Doses (DDD, World Health Organisation) as knowledge bases for an alerting system. METHODS In a large set of critical-dose drugs (N = 140) we compared MRTD(FDA) and DDD values with the corresponding German MRTD(SPC). We then retrospectively assessed a set of 633 electronically prescribed drugs (EPDs) issued at a university hospital and calculated prescription rates of excessive doses. RESULTS MRTD(FDA) was similar to MRTD(SPC) in 37% (N = 140), higher in 32%, and lower in 31% of drugs. On average, available DDD values (N = 129) were 1.6 times lower than MRTD(SPC), with 64% being lower, 33% similar, and 3% larger than MRTD(SPC). Prescription rates of excessive doses according to MRTD(FDA) were 2.5-fold higher (6.1%) than according to MRTD(SPC) (2.5%) (p < 0.01). However, only one in four EPDs categorised as overdosed according to MRTD(FDA) exceeded MRTD(SPC), and MRTD(FDA) values were available only for 67% of all assessed EPDs. CONCLUSION Our study revealed a remarkable number of prescriptions with doses exceeding approved limits. Their prevention appears feasible but the choice of an appropriate database for MRTDs is essential, and differences between available information sources are large.
Collapse
Affiliation(s)
- H M Seidling
- Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
| | | | | | | | | | | |
Collapse
|
44
|
Josephson F, Allqvist A, Janabi M, Sayi J, Aklillu E, Jande M, Mahindi M, Burhenne J, Bottiger Y, Gustafsson LL, Haefeli WE, Bertilsson L. CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir. Clin Pharmacol Ther 2007; 81:708-12. [PMID: 17329995 DOI: 10.1038/sj.clpt.6100117] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
CYP3A is the main enzyme subfamily involved in the metabolism of the HIV protease-inhibitor saquinavir. We hypothesized that individuals homozygous for CYP3A5*1 might have a higher oral clearance of saquinavir, compared with subjects lacking functional CYP3A5 alleles. A single-dose pharmacokinetic trial of saquinavir soft gel capsules, 1,200 mg, was performed in 16 black Tanzanian healthy volunteers with two functional CYP3A5 alleles (*1/*1) and in 18 volunteers without functional CYP3A5 alleles (both alleles being either *3, *6, or *7). The median area under the plasma concentration-time curve (AUC)0-24 reached among subjects with two functional alleles was 1,410 ng h/ml (interquartile range (IQR) 826-1,929), whereas it was 2,138 ng h/ml (IQR 1,380-3,331) in subjects without (P=0.0533, Mann-Whitney U-test). The median ratio of saquinavir over its M2 plus M3 hydroxy metabolites in urine was 64 (IQR 52-73) in subjects with two functional alleles, whereas it was 145 (IQR 89-181) in those without (P=0.000078, Mann-Whitney U-test). In conclusion, saquinavir is metabolized by CYP3A5. The median AUC0-24 for saquinavir among individuals with two functional CYP3A5 alleles was 34% lower than among those with no functional alleles. To clarify the clinical importance of the CYP3A5 polymorphism, further studies should be conducted on saquinavir, dosed to steady state, in the presence of ritonavir boosting.
Collapse
Affiliation(s)
- F Josephson
- Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska University Hospital, Huddinge, Karolinska Institutet, Stockholm, Sweden.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Abstract
Ein 64-jähriger Patient mit gut eingestellter essentieller Hypertonie berichtet überzeugend vom Therapieerfolg mit Yohimbin in der Akutbehandlung seiner erektilen Dysfunktion. Er wünscht die Verschreibung dieser Substanz, wovon wiederum sein Arzt nicht begeistert ist, da Akuteffekte dieser Behandlung ungewöhnlich sind und die Blockade von α2-adrenergen Rezeptoren den Blutdruck erhöhen kann. Sie einigen sich auf die Objektivierung von Wirksamkeit oder Versagen von Yohimbin in einer experimentellen Untersuchung nach einem Single Case Randomized Trial Design, also einer kontrollierten Versuchsanordnung in einem Einzelpatienten mit doppelblinder Durchführung. Der zehnmalige Vergleich von Placebo und oralem Yohimbin ließ keinen Unterschied erkennen und verhinderte, dass der Patient mit einer potenziell schädlichen Arzneimittel-Kombination exponiert wurde.
Collapse
|
46
|
Quinzler R, Gasse C, Schneider A, Kaufmann-Kolle P, Szecsenyi J, Haefeli WE. The frequency of inappropriate tablet splitting in primary care. Eur J Clin Pharmacol 2006; 62:1065-73. [PMID: 17024485 DOI: 10.1007/s00228-006-0202-3] [Citation(s) in RCA: 75] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2006] [Accepted: 08/16/2006] [Indexed: 10/24/2022]
Abstract
INTRODUCTION We assessed the frequency and determinants of tablet splitting in primary care in Germany and evaluated the quality of information on divisibility in the Summary of Product Characteristics (SPCs) and in the Package Leaflet (PL) as legal sources of information for health care providers and patients. METHODS We performed a cross-sectional questionnaire survey among patients of 59 general practitioners in the German Federal State Saxony-Anhalt in 2005 in order to collect detailed information on all drugs of patients maintained on more than three drugs. RESULTS The response rate was 82.1% (n=905) and 3,158 drugs (tablets and dragées) were included in the analyses. Of all drugs, 24.1% were split (762 of 3,158): 8.7% of all split tablets were unscored (66 of 762) and 3.8% of all split tablets were not allowed to be split (29 of 762). Tablets of the higher price categories and higher strengths were twice as likely to be split. Only 22.5% of the SPCs (9 of 40) of the split unscored tablet brands contained explicit information on divisibility and only 36.4% of the PLs (8 of 22) of the split brands that were not allowed to be split stated that splitting was not appropriate. CONCLUSION The splitting of tablets in primary care is a frequent habit likely driven by medical and economic considerations. Almost 1% of all tablets are split that must not be fragmented. However, the SPC and PL provide only limited information on divisibility stressing the need to improve this information promptly to avoid medication errors.
Collapse
Affiliation(s)
- R Quinzler
- Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
| | | | | | | | | | | |
Collapse
|
47
|
Abstract
More than 100 different routes of drug administration are known for which highly specialised galenic formulations and sophisticated containers and application devices have been developed. Consequently substantial knowledge is required to use them in a proper and most successful way. The trend of moving the responsibility for drug application to patients and care givers necessitates their appropriate and comprehensive information to enable them to administer medication safely, skilfully, and correctly. This also includes practical skills for instance to open blisters and containers, to split tablets when needed, and to inhale, inject, or ingest the drugs. This article compiles the areas of information which should be covered, communicated, and checked by the prescribing physician and the dispensing pharmacist to maximise the patients' odds for a successful therapy.
Collapse
Affiliation(s)
- W E Haefeli
- Abteilung Innere Medizin VI, Klinische Pharmakologie und Pharmakoepidemiologie, Medizinische Klinik (Krehl-Klinik), Universitätsklinikum Heidelberg.
| |
Collapse
|
48
|
Abstract
Knapp ein Drittel der ambulanten Patienten teilen ihre Tabletten vor der Einnahme. Diese gängige Praxis birgt, neben etlichen Vorteilen, allerdings auch einige Risiken für die Arzneimitteltherapie. Vor allem ältere Patienten sind häufig nicht in der Lage Tabletten exakt zu teilen und die unsachgemäße Teilung z.B. von Retardpräparaten kann zu einer Überdosierung führen. Ob eine Tablette geteilt werden darf, hängt im Wesentlichen von den Wirkstoffeigenschaften, der Galenik, der Form der Tablette und der Beschaffenheit der Bruchkerbe ab. Darüber hinaus muss gesichert sein, dass der Patient über die erforderliche Bereitschaft und Fingergeschicklichkeit verfügt, seine Tabletten zu teilen, um die Compliance nicht zu beeinträchtigen. Nicht zuletzt muss der Patient über die richtige Teilungstechnik informiert sein, damit beim Teilen zwei gleichgroße Bruchstücke entstehen und die Wirksamkeit der Therapie nicht gefährdet wird.
Collapse
Affiliation(s)
- R Quinzler
- Abteilung Innere Medizin VI, Klinische Pharmakologie und Pharmakoepidemiologie, Medizinische Klinik (Krehl-Klinik), Universitätsklinikum Heidelberg
| | | |
Collapse
|
49
|
Abstract
BACKGROUND AND OBJECTIVE In selecting drugs for treatment during pregnancy and breastfeeding it is essential to be certain of their safety. But categories are lacking that systematically relate the current state of knowledge of individual substances--rather than just drug classes--to each trimester of pregnancy. As such a stratification of risk would be helpful, it was the aim of this study to propose a new and more differentiated classification. METHODS Internationally available literature and electronic data bases providing details on adverse effects of individual drugs during pregnancy and breastfeeding as well as summaries of product characteristics of the drugs served as comprehensive sources of information. Account was taken of compound-specific data on toxicity during the reproductive and developmental stages, genotoxicity and carcinogenicity (in animals and in-vitro experiments) and drug-specific experience as documented in women during pregnancy and breastfeeding. RESULTS A new risk classification and appropriate recommendations for clinical management were developed to ensure the safety of drugs given during pregnancy and breastfeeding, taking into account the varying risks during the three trimesters of pregnancy and the perinatal period. Antibiotics were selected as a model for drugs in general and classified according to the new system. CONCLUSION The proposed new classification of risk makes it possible to select safe agents in the treatment of pregnant and/or breastfeeding women. It is based on the current state of knowledge about a particular substance, also in relationship to the developmental phase of the breastfed child.
Collapse
Affiliation(s)
- T Bertsche
- Medizinische Klinik (Krehl-Klinik), Abteilung Innere Medizin VI, Klinische Pharmakologie und Pharmakoepidemiologie, Universitätsklinikum Heidelberg
| | | | | | | | | |
Collapse
|
50
|
Knaup P, Pilz J, Kaltschmidt J, Ludt S, Szecsenyi J, Haefeli WE. Standardized documentation of drug recommendations in discharge letters--a contribution to quality management in cooperative care. Methods Inf Med 2006; 45:336-42. [PMID: 16964347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
OBJECTIVES To analyze the necessity and potential usefulness of a computerized physician order entry (CPOE) system in supporting the writing of pharmacotherapeutic recommendations in discharge letters. METHODS Systematic analysis of drug recommendations in discharge letters of a hospital providing tertiary care, structured interviews with in-hospital prescribers, and focus groups with general practitioners who admit patients to this hospital. RESULTS We analyzed 1800 randomly selected discharge letters, 1205 of which contained pharmacotherapeutic recommendations. The frequencies, structure, and quality of these recommendations varied considerably between departments. Nearly 16% of the recommendations contained both proprietary (brand) and non-proprietary names (active ingredient). Interviewed clinicians expressed interest in CPOE systems that check for contraindications and interactions between drugs, suggest cheaper products, and automatically insert active ingredients when omitted. The focus group sessions confirmed that the pharmacotherapeutic recommendations in current discharge letters do not effectively support daily clinical practice. CONCLUSIONS Documenting active ingredients as well as brand names in drug therapy recommendations is currently not part of clinical practice. Computerized decision support can help to optimise the structure and communication of therapeutic information across interfaces and can be a quality factor with considerable influence on process quality, outcome quality, and costs of cooperative patient care.
Collapse
Affiliation(s)
- P Knaup
- University of Heidelberg, Department of Medical Informatics, 69120 Heidelberg, Germany.
| | | | | | | | | | | |
Collapse
|